HGF and hepatocellular carcinoma: While well-established oncogenic pathways like c-Met/HGF, TGF-β, and FGFR remain important therapeutic targets for the development of novel therapies or combinations in HCC, several new targetable pathways have been identified for HCC in the last few years.